UroGen Pharma Ltd. (URGN) stock
URGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
$29.79−0.08 (-0.27%)
Close on Nov 18, 2026Market cap $1.46BP/E –Yield –
UroGen Pharma operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
UroGen Pharma's operating income for the twelve months ending Jun 30, 2026 was -$66.65M. For fiscal 2025 it was -$124.86M. The highest annual figure on record is $798.00K in fiscal 2016.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$124.86M | – |
| FY2024 | Dec 31, 2024 | -$96.78M | – |
| FY2023 | Dec 31, 2023 | -$65.54M | – |
| FY2022 | Dec 31, 2022 | -$79.04M | – |
| FY2021 | Dec 31, 2021 | -$92.29M | – |
| FY2020 | Dec 31, 2020 | -$126.74M | – |
| FY2019 | Dec 31, 2019 | -$109.48M | – |
| FY2018 | Dec 31, 2018 | -$77.18M | – |
| FY2017 | Dec 31, 2017 | -$19.95M | -2600.0% |
| FY2016 | Dec 31, 2016 | $798.00K | – |
| FY2015 | Dec 31, 2015 | -$12.41M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $111.00K | – |
| Q1 FY2026 | Mar 31, 2026 | -$20.26M | – |
| Q4 FY2025 | Dec 31, 2025 | -$19.12M | – |
| Q3 FY2025 | Sep 30, 2025 | -$27.39M | – |
| Q2 FY2025 | Jun 30, 2025 | -$41.45M | – |
| Q1 FY2025 | Mar 31, 2025 | -$36.91M | – |
| Q4 FY2024 | Dec 31, 2024 | -$27.66M | – |
| Q3 FY2024 | Sep 30, 2024 | -$17.55M | – |
| Q2 FY2024 | Jun 30, 2024 | -$25.84M | – |
| Q1 FY2024 | Mar 31, 2024 | -$25.74M | – |
| Q4 FY2023 | Dec 31, 2023 | -$14.61M | – |
| Q3 FY2023 | Sep 30, 2023 | -$13.50M | – |
| Q2 FY2023 | Jun 30, 2023 | -$15.38M | – |
| Q1 FY2023 | Mar 31, 2023 | -$22.05M | – |
| Q4 FY2022 | Dec 31, 2022 | -$20.28M | – |
| Q3 FY2022 | Sep 30, 2022 | -$18.09M | – |
| Q2 FY2022 | Jun 30, 2022 | -$18.72M | – |
| Q1 FY2022 | Mar 31, 2022 | -$21.96M | – |
| Q4 FY2021 | Dec 31, 2021 | -$19.92M | – |
| Q3 FY2021 | Sep 30, 2021 | -$23.44M | – |
| Q2 FY2021 | Jun 30, 2021 | -$22.82M | – |
| Q1 FY2021 | Mar 31, 2021 | -$26.11M | – |
| Q4 FY2020 | Dec 31, 2020 | -$27.25M | – |
| Q3 FY2020 | Sep 30, 2020 | -$29.12M | – |
| Q2 FY2020 | Jun 30, 2020 | -$31.80M | – |
| Q1 FY2020 | Mar 31, 2020 | -$38.56M | – |
| Q4 FY2019 | Dec 31, 2019 | -$39.84M | – |
| Q3 FY2019 | Sep 30, 2019 | -$23.45M | – |
| Q2 FY2019 | Jun 30, 2019 | -$23.75M | – |
| Q1 FY2019 | Mar 31, 2019 | -$22.43M | – |
| Q4 FY2018 | Dec 31, 2018 | -$24.02M | – |
| Q3 FY2018 | Sep 30, 2018 | -$21.09M | – |
| Q2 FY2018 | Jun 30, 2018 | -$18.43M | – |
| Q1 FY2018 | Mar 31, 2018 | -$13.64M | – |
| Q4 FY2017 | Dec 31, 2017 | -$10.16M | – |
| Q3 FY2017 | Sep 30, 2017 | -$303.00K | – |
| Q2 FY2017 | Jun 30, 2017 | -$5.95M | – |
| Q1 FY2017 | Mar 31, 2017 | -$3.54M | – |
See a number that looks wrong?